Comparative Pharmacology
Head-to-head clinical analysis: INAPSINE versus MELLARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INAPSINE versus MELLARIL.
INAPSINE vs MELLARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category C
Antipsychotic
Antipsychotic